Most Read Articles
3 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 22 hours ago
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.
2 days ago
Duodenal eosinophilia carries up to a sixfold increased risk of developing gastro-oesophageal reflux disease (GERD) over 10 years in individuals with functional dyspepsia (FD) and postprandial distress syndrome (PDS), a study has found.

Intensive BP treatment cardioprotective in T2DM patients receiving standard glycaemic control

07 Aug 2018

Intensive blood pressure (BP) treatment yields a significant reduction in the risk of cardiovascular events, including heart failure, in patients with type 2 diabetes mellitus (T2DM) receiving standard but not intensive glycaemic control therapy, as shown in a recent study.

The present analysis included T2DM patients (mean age 62.8 years; 48 percent female) enrolled in the ACCORD BP trial (Action to Control Cardiovascular Risk in Diabetes Blood Pressure). There were 2,362 patients receiving standard glucose-lowering therapy (standard BP treatment, n=1,178; intensive BP, n=1,184) and 2,371 on intensive glycaemic control treatment (standard BP, n=1,193; intensive BP, n=1,178).

During a mean follow-up of 4.5 years, the primary outcome of a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke and hospitalized congestive heart failure occurred in 528 patients overall. In the standard glycaemic control group, the risk of a cardiovascular event was significantly lower among patients receiving intensive vs standard BP therapy (hazard ratio [HR], 0.71; 95 percent CI, 0.56–0.90; p=0.005). In the intensive glycaemic control group, on the other hand, the risk did not significantly differ between the two BP treatment subgroups (HR, 1.06; 0.83–1.36; p=0.61).

Similar results were found for stroke risk, which was markedly lower among patients in the standard glycaemic control group receiving intensive BP treatment. Such risk reduction was absent in the intensive glycaemic control group.

A nonsignificant increase in all-cause mortality risk was seen among patients in the intensive glycaemic control group receiving intensive vs standard BP treatment (HR, 1.38; 0.99–1.92; p=0.05).

Researchers pointed out that the benefits of intensive BP treatment were observed only in ACCORD BP patients receiving standard glycaemic control without additional risk factors. Additional studies are warranted to confirm the safety and efficacy of intensive BP treatment in high-risk patients with T2DM.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, 3 days ago
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 22 hours ago
Patients with rheumatoid arthritis (RA) who maintained their disease remission had a significantly reduced risk of clinical and subclinical atherosclerosis, according to the 3-year follow-up data of the GIRRCS* study presented at EULAR 2019.
2 days ago
Duodenal eosinophilia carries up to a sixfold increased risk of developing gastro-oesophageal reflux disease (GERD) over 10 years in individuals with functional dyspepsia (FD) and postprandial distress syndrome (PDS), a study has found.